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Items for this week’s EPI Update include: 
• Vaccination still best defense against flu  
• Neurocysticercosis case identified in Iowa 
• FDA streamlines updating of antimicrobial susceptibility breakpoints 
• Babesiosis in Iowa 
• In the news: Guano-filled tunnels cause deadly outbreak in 
Dominican Republic 
• Infographic: Keep hot foods above 140⁰F 
• Meeting announcements and training opportunities 
 
Vaccination still best defense against flu  
A recent New England Journal of Medicine article cited studies conducted in 
Australia indicating the effectiveness of this year’s influenza vaccine there was 
about 10 percent against H3N2 virus and 33 percent against all influenza viruses. 
This article has prompted questions about how effective the influenza vaccine will 
be in the U.S. this season. While it is too early to know how effective this year’s 
vaccine will be, information from previous years provides clues. 
 
Influenza vaccine effectiveness varies from year to year among different age and 
risk groups and is affected by the circulating viruses that season. This season’s 
vaccine includes the same H3N2 vaccine component as last season and most 
H3N2 viruses characterized in the U.S. this season are still similar to the H3N2 
vaccine strain. Therefore, last season’s estimates of vaccine effectiveness from 
the U.S are likely to be a better predictor of vaccine effectiveness in the U.S. this 
year than estimates from Australia’s season. Last season, the vaccine 
effectiveness in the U.S. was about 40 percent overall and 32 percent against 
H3N2 viruses. 
 
No vaccine is 100 percent effective, but there are many reasons to get 
vaccinated for influenza. It is the best way to prevent influenza-related illness, 
serious complications and death. Even with vaccine effectiveness in the range of 
30 to 60 percent, influenza vaccination prevents millions of illnesses and tens of 
thousands of hospitalizations each year. 
 
It is important to take other protective actions, such as the 3 Cs: cover your 
cough, clean your hands, and contain germs by staying home when ill. Antivirals 
can be prescribed as a second line of defense to treat influenza and to prevent 
illness in certain high risk settings, such as long-term care facilities, during 
suspected influenza outbreaks. 
 
For answers to frequently asked questions about influenza, visit 
www.cdc.gov/flu/about/season/flu-season-2017-2018.htm. 
 
Neurocysticercosis case identified in Iowa 
A case of neurocysticercosis in an Iowa resident was reported this week. 
Cysticercosis is a parasitic infection caused by larval cysts of the tapeworm 
Taenia solium. Infection typically occurs after swallowing eggs excreted in the 
stool of an infectious individual who has the tapeworm. Once consumed, the 
larval cysts have the potential to infect the brain, muscles or other tissues. The 
parasite is found worldwide, but is more common in rural areas of Latin America, 
Asia and Africa with poor water quality and sanitation practices. The infected 
Iowa resident did have out-of-country travel to a high risk area.  
 
Neurocysticercosis symptoms include seizures, headaches, confusion and 
tender lumps under the skin. Household members of someone ill with this 
infection are at increased risk of contracting this illness, so testing is 
recommended for those individuals. 
 
For more information about this illness, visit 
www.cdc.gov/parasites/cysticercosis/index.html. 
 
FDA streamlines updating of antimicrobial susceptibility breakpoints 
When a patient has an infection, healthcare providers often order antimicrobial 
susceptibility testing to help them select a drug that is likely to work against the 
infection. The criteria used to determine whether bacteria or fungi are considered 
“susceptible” or “resistant” to a particular drug are referred to as breakpoints, or 
more formally as Susceptibility Test Interpretative Criteria (STIC). Over time, 
bacteria and fungi may become less susceptible to some drugs. When this 
happens, breakpoints may need to be changed so that laboratories are using the 
most up-to-date information to help healthcare providers choose appropriate 
treatment. 
 
This week, FDA took an important first step in implementing a more streamlined 
process of updating breakpoints for antimicrobial drugs by launching new web 
pages that contain Susceptibility Test Interpretive Criteria. 
 
For more information on FDA-Recognized Antimicrobial Susceptibility Test 




Babesiosis in Iowa 
While Lyme disease is the most commonly reported tick-borne disease in Iowa, it 
is not the only tick-borne infection of concern. One of the rarest, but important 
tick-borne infections that is not well known is Babesiosis. Babesiosis is usually 
caused by the parasite Babesia microti, which infects red blood cells. The 
parasite is spread by the blacklegged tick (or deer tick), the same tick that 
spreads Lyme disease in Iowa. Babesiosis in the U.S. mainly occurs in parts of 
the Northeast and upper Midwest. 
 
In 2016, one case of Babesiosis was reported to IDPH. In 2017, two cases have 
been reported and another is under investigation. 
 
For more information on Babesiosis, visit www.cdc.gov/parasites/babesiosis/. 
 






Infographic: Keep hot foods above 140⁰ F 
 
 
To view in full-size, visit www.cdc.gov/foodsafety/images/socialmedia/Holiday-
gingerbread-buffet2-fb.png.  
 
Meeting announcements and training opportunities 
None 
 
Distribution of this issue of the EPI Update was delayed due to technical 
challenges.  The next EPI Update will be issued on Friday, December 29th.   
 
Have a healthy and happy week! 
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